Last updated: September 23, 2026
BEXXAR, the trade name for the tositumomab and iodine I-131 tositumomab therapeutic regimen, was FDA-approved in 2003 for relapsed or refractory CD20-positive non-Hodgkin lymphoma. Its commercial trajectory was weak despite clinical activity. Limited use of radioimmunotherapy, complex administration, radiation-handling requirements, reimbursement friction, competition from rituximab-based regimens and the absence of a broad treatment-market strategy constrained revenue. GlaxoSmithKline withdrew BEXXAR from the U.S. market in 2014 for commercial reasons. The product no longer has an active commercial market in the United States.[1-4]
What was BEXXAR and how did its treatment regimen work?
BEXXAR combined an anti-CD20 monoclonal antibody with radioactive iodine-131.
| Attribute |
BEXXAR profile |
| Active biologic |
Tositumomab, a murine anti-CD20 monoclonal antibody |
| Radioactive component |
Iodine I-131 linked to tositumomab |
| FDA approval |
June 27, 2003 |
| Original indication |
Relapsed or refractory CD20-positive non-Hodgkin lymphoma |
| Administration |
Unlabeled dosimetric dose followed by therapeutic radiolabeled dose |
| Treatment setting |
Specialized nuclear medicine, hematology and radiation-oncology centers |
| Original sponsor |
Corixa Corp. |
| Later commercial owner |
GlaxoSmithKline |
| U.S. commercial status |
Withdrawn in 2014 |
| Current U.S. availability |
Not commercially marketed |
The regimen required an initial antibody dose to evaluate biodistribution and calculate the patient-specific therapeutic radioactivity. The treatment then delivered beta radiation to CD20-positive lymphoma cells. This individualized process created operational complexity that conventional anti-CD20 antibodies did not have.[1]
The product was intended for patients with relapsed or refractory follicular or transformed non-Hodgkin lymphoma. The FDA label stated that BEXXAR had not been studied in patients with bulky disease or in combination with chemotherapy in the same manner as standard systemic regimens.[1]
When did BEXXAR lose exclusivity and commercial availability?
BEXXAR’s key commercial event was withdrawal, not generic or biosimilar substitution.
| Date |
Event |
| June 2003 |
FDA approved BEXXAR for relapsed or refractory CD20-positive non-Hodgkin lymphoma |
| 2005 |
GlaxoSmithKline acquired Corixa and its oncology assets |
| 2008-2013 |
Product remained available through a limited specialist-center model |
| February 2014 |
GSK announced plans to discontinue BEXXAR production and distribution |
| August 2014 |
U.S. commercial withdrawal was completed |
| After 2014 |
No standard U.S. generic launch followed |
GSK attributed the withdrawal to commercial considerations. The company did not identify a new safety signal as the reason for discontinuation.[2,3]
BEXXAR’s market life was therefore shorter than its potential patent life. Patent expiry did not determine the end of revenue generation. The commercial system needed to manufacture, transport, administer and dispose of a radioactive biologic was economically unsustainable at the product’s level of demand.
What was BEXXAR’s financial trajectory?
Standalone BEXXAR revenue was not separately reported in the principal public filings of Corixa or GSK. The product was included within broader oncology or pharmaceutical segment reporting. Public disclosures indicate a low-revenue product relative to the scale required to support a specialized radiopharmaceutical infrastructure.[3-5]
Commercial development under Corixa
Corixa commercialized BEXXAR as a specialist treatment for relapsed lymphoma. Its commercial model depended on a limited network of qualified treatment centers rather than broad community oncology distribution. That model restricted patient access and raised the cost of sales.
Corixa’s business was later acquired by GSK. The acquisition transferred BEXXAR into a large pharmaceutical portfolio, but scale did not solve the product’s underlying market problems. BEXXAR competed against established rituximab-based treatment pathways that were easier to administer and more familiar to oncologists.
GSK ownership and withdrawal
GSK’s decision to discontinue BEXXAR reflected the product’s limited commercial return. Key constraints included:
- Low patient volumes.
- A narrow indication in relapsed or refractory lymphoma.
- Requirement for specialized radiation facilities.
- Patient-specific dosimetry.
- Regulatory controls for radioactive materials.
- Competition from rituximab and chemotherapy combinations.
- Reimbursement and referral barriers.
- The need to maintain manufacturing and distribution capabilities for a small market.
The absence of a separately disclosed BEXXAR revenue line prevents a reliable year-by-year sales reconstruction. Claims that assign precise annual BEXXAR revenue should be treated cautiously unless supported by company filings or audited transaction documents.
How did BEXXAR compare with Zevalin and rituximab?
BEXXAR competed against both another radioimmunotherapy product and conventional anti-CD20 treatment.
| Product |
Technology |
Principal commercial advantage |
Principal commercial barrier |
| BEXXAR |
I-131-labeled tositumomab |
Patient-specific radioimmunotherapy with durable responses in selected lymphoma patients |
Complex dosimetry, radiation precautions and limited center availability |
| Zevalin |
Y-90-labeled ibritumomab tiuxetan |
Radioimmunotherapy without the same imaging and dosimetry structure used by BEXXAR |
Nuclear medicine logistics, reimbursement and weak physician adoption |
| Rituxan/MabThera |
Unlabeled rituximab anti-CD20 antibody |
Broad familiarity, established infusion pathways and extensive combination use |
Infusion burden, resistance and competition from later anti-CD20 agents |
BEXXAR and Zevalin demonstrated that clinical activity alone was insufficient to establish radioimmunotherapy as a mainstream lymphoma category. Rituximab became embedded in treatment guidelines, hospital protocols and community oncology workflows. Radioimmunotherapy remained concentrated in specialist centers.
The commercial comparison favored rituximab because its delivery model was simpler. Conventional infusion did not require radioactive-material licensing, dedicated radiation rooms or patient-specific isotope calculations.
What FDA regulatory status did BEXXAR have?
BEXXAR was approved under a biologics license application rather than an abbreviated generic-drug pathway. The product’s regulatory status was unusual because it combined:
- A monoclonal antibody.
- A radioisotope.
- A dosimetric procedure.
- Radiation-safety controls.
- A patient-specific therapeutic activity calculation.
The FDA-approved labeling required monitoring for severe cytopenias, infusion reactions, human anti-mouse antibodies and other toxicities associated with the regimen.[1]
The product’s withdrawal was commercial. FDA withdrawal notices and company communications did not indicate that the approval was removed because of an efficacy or safety failure.[2,3]
What patents protected BEXXAR?
BEXXAR’s intellectual-property position was more complex than a conventional small-molecule drug patent estate.
Potential protection categories included:
- Anti-CD20 antibody composition claims.
- Radiolabeled antibody compositions.
- Methods for treating B-cell lymphoma.
- Patient-specific dosimetry methods.
- Manufacturing and conjugation processes.
- Radiation-administration protocols.
- Use of iodine-131-labeled antibody in lymphoma.
Publicly accessible sources do not establish a single, current patent expiration date that controlled BEXXAR’s commercial life. The central commercial constraint was market economics, not a documented patent cliff.
BEXXAR was not a conventional small-molecule product eligible for an ANDA-based generic substitution. A follow-on product would need to address the antibody, radiolabeling process, manufacturing controls, clinical comparability and radiation-handling requirements. The practical development pathway would be closer to a complex biologic or radiopharmaceutical program than to a standard generic.
Did BEXXAR face Paragraph IV challenges or biosimilar competition?
No commercially material Paragraph IV generic challenge is associated with BEXXAR’s withdrawal. Paragraph IV litigation is principally relevant to small-molecule products approved under the Hatch-Waxman framework. BEXXAR’s biologic and radiopharmaceutical structure made that pathway inapplicable to the product in the same way it applies to conventional tablets or injectable small molecules.
No biosimilar competitor displaced BEXXAR in the United States. A biosimilar program would have faced several barriers:
- The reference product was no longer commercially supplied.
- The radioactive iodine component creates product-comparability issues.
- The therapeutic regimen involves patient-specific dosimetry.
- The product requires specialized manufacturing and distribution.
- The market is too small to support ordinary biosimilar economics.
The absence of biosimilar entry does not indicate a strong surviving patent estate. It reflects the limited commercial opportunity and technical complexity of recreating the regimen.
What manufacturing and intellectual-property barriers affected BEXXAR?
BEXXAR required coordination between biologic manufacturing and radiopharmaceutical operations. The manufacturer needed to maintain:
- Consistent antibody production.
- Controlled iodine-131 conjugation.
- Radioactive material licensing.
- Validated release testing.
- Short-window distribution logistics.
- Qualified treatment-center infrastructure.
- Procedures for radiation exposure and waste management.
Iodine-131 also imposes supply-chain constraints because of radioactive decay. Distribution timing, dose calibration and treatment scheduling affect the economic value of each manufactured unit. Inventory cannot be managed like a conventional monoclonal antibody.
These barriers reduced manufacturing flexibility and raised fixed costs. A low-volume product could not spread those costs across a sufficiently large patient base.
Which companies challenged BEXXAR commercially?
BEXXAR’s principal commercial competitors were not generic manufacturers. They were:
- Genentech and Biogen Idec’s rituximab, marketed in the United States as Rituxan.
- Spectrum Pharmaceuticals’ Zevalin program.
- Chemotherapy regimens used in relapsed lymphoma.
- Later anti-CD20 and targeted lymphoma therapies.
The most important competitive pressure came from treatment substitution. Physicians could select established rituximab-based regimens without sending patients to a specialized radioimmunotherapy center.
What generic-entry risks existed after BEXXAR withdrawal?
The direct generic-entry risk was low because the product was already withdrawn. The more relevant issue was replacement by alternative lymphoma therapies.
Potential replacement categories included:
- Rituximab-based regimens.
- Obinutuzumab-based therapy.
- Bendamustine combinations.
- Lenalidomide-based treatment.
- BTK inhibitors.
- PI3K inhibitors, subject to changing regulatory status.
- CAR-T cell therapy for eligible patients.
- Bispecific antibodies and other immune-engaging therapies.
BEXXAR’s discontinuation removed a treatment option rather than creating a conventional patent-expiry opportunity. Any new entrant would need to build a market, treatment infrastructure and reimbursement pathway rather than simply offer a lower-priced equivalent.
What was BEXXAR’s geographic coverage?
BEXXAR was primarily a U.S. commercial product. Its practical geographic reach was limited by the availability of licensed facilities and trained personnel. Even within the United States, access depended on referral to centers capable of administering radioimmunotherapy.
The product’s limited center network reduced prescribing frequency. International commercialization was also constrained by local radiation regulation, isotope supply, reimbursement systems and specialist infrastructure.
How strong was the BEXXAR patent estate?
BEXXAR had meaningful technical protection opportunities but limited residual commercial value after withdrawal.
| Patent-estate factor |
Assessment |
| Antibody composition |
Potentially important historically, but age and prior-art exposure reduced remaining leverage |
| Radiolabeled composition |
Technically relevant and difficult to reproduce at scale |
| Method of treatment |
Potentially narrow because of patient selection and dosing limitations |
| Dosimetry |
Operationally important, but difficult to enforce as a standalone commercial barrier |
| Manufacturing |
Could protect process know-how and quality controls |
| Current commercial strength |
Low after withdrawal and absence of active U.S. marketing |
| Generic litigation exposure |
Low |
| Biosimilar exposure |
Low, primarily because of market and technical barriers |
The product’s strongest defenses were operational and regulatory rather than clearly identifiable patent exclusivity. A competitor would have faced a difficult development program, but that difficulty did not translate into a viable market for BEXXAR.
What is the current investment and licensing outlook for BEXXAR?
BEXXAR has no meaningful current commercial revenue stream. Its residual value is principally historical or scientific:
- Prior clinical data on radioimmunotherapy.
- Technical knowledge regarding I-131-labeled antibodies.
- Potentially useful manufacturing and dosimetry know-how.
- Lessons for targeted radiopharmaceutical development.
- Possible academic or investigational use, subject to regulatory and supply constraints.
A licensing transaction centered on commercial relaunch would face substantial obstacles. The licensee would need to rebuild manufacturing, regulatory support, treatment-center access and physician adoption. A more plausible value proposition would involve platform know-how or historical data rather than relaunching BEXXAR as a standalone product.
Key Takeaways
- BEXXAR was FDA-approved in 2003 as an I-131-labeled anti-CD20 radioimmunotherapy.
- GSK withdrew the product from the U.S. market in 2014 for commercial reasons.
- Public filings do not provide a reliable standalone annual revenue series.
- The main commercial problems were low volume, complex administration, radiation controls and competition from rituximab-based treatment.
- No material Paragraph IV generic challenge or biosimilar displacement drove the product’s decline.
- BEXXAR’s practical barriers were manufacturing, infrastructure and reimbursement-related, not only patent-related.
- The product has no meaningful current U.S. commercial revenue exposure.
- Any relaunch would require rebuilding an entire specialist treatment network.
FAQs
Is BEXXAR still available in the United States?
No. GSK discontinued U.S. production and commercial distribution in 2014.
Did BEXXAR fail because of safety concerns?
No regulatory record identifies a new safety issue as the reason for withdrawal. The stated reason was commercial viability.
Was BEXXAR a biosimilar or generic drug?
No. BEXXAR was a biologic radioimmunotherapy regimen approved under a biologics license application.
Why did rituximab outperform BEXXAR commercially?
Rituximab fit existing infusion and oncology workflows, had broader combination use and did not require radioactive-material handling or patient-specific dosimetry.
Could a company relaunch BEXXAR after its withdrawal?
A relaunch would require regulatory, manufacturing, isotope-supply and treatment-center capabilities. The principal obstacle would be rebuilding a commercially viable market, not simply obtaining rights to an expired product.
References
- U.S. Food and Drug Administration. (2003). BEXXAR (tositumomab and iodine I-131 tositumomab) prescribing information.
- GlaxoSmithKline. (2014). BEXXAR product discontinuation communication.
- U.S. Food and Drug Administration. (2014). BEXXAR withdrawal and product availability information.
- Corixa Corporation. (2004-2005). Annual reports and securities filings.
- GlaxoSmithKline plc. (2005-2014). Annual reports and pharmaceutical portfolio disclosures.
